User: Guest  Login
Document type:
journal article 
Author(s):
Lück, Hans-Joachim; Du Bois, Andreas; Loibl, Sibylle; Schrader, Iris; Huober, Jens; Heilmann, Volker; Beckmann, Matthias; Stähler, Ann; Jackisch, Christian; Hubalek, Michael; Richter, Barbara; Stickeler, Elmar; Eidtmann, Holger; Thomssen, Christoph; Untch, Michael; Wollschläger, Kerstin; Schuster, Tibor; von Minckwitz, Gunter 
Title:
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. 
Abstract:
Capecitabine/taxane combinations are highly active in metastatic breast cancer (MBC). We conducted a randomized, phase III, noninferiority trial comparing capecitabine plus paclitaxel (XP) with epirubicin plus paclitaxel (EP) as first-line therapy for MBC, regarding progression-free survival (PFS) as primary efficacy endpoint. Females who had received no prior chemotherapy for MBC were randomized to six 3-weekly cycles of XP (capecitabine 1000 mg/m(2) b.i.d., days 1-14; paclitaxel 175 mg/m(2) 3...    »
 
Journal title abbreviation:
Breast Cancer Res Treat 
Year:
2013 
Journal volume:
139 
Journal issue:
Pages contribution:
779-87 
Language:
eng 
Print-ISSN:
0167-6806 
TUM Institution:
Institut für Medizinische Statistik und Epidemiologie